insights_auto
Why is HELP down 16.94%?
Dive Deeperchevron_right
HELP:NASDAQ
Helus Pharma Inc.
$8.80
arrow_downward
-16.94%(-1.80) 1D
$8.79
arrow_downward
-0.11% (-0.010)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HELP...
Open
$10.80
High
$10.85
Low
$8.32
Avg. vol.
1.47M
Volume
0.00
52-wk high
$15.15
52-wk low
$3.76
Beta
0.53
Shares outstanding
73.06M
No. of employees
100
Open
$10.80
High
$10.85
Low
$8.32
Avg. vol.
1.47M
Volume
0.00
52-wk high
$15.15
52-wk low
$3.76
Beta
0.53
Shares outstanding
73.06M
No. of employees
100
News stories
From web sources and news partners
Markets Media
·
32 minutes ago
NYSE Expands Network of Transfer Agents
BeInCrypto
·
58 minutes ago
Anthropic’s Amended IPO Filing in 5 Numbers Before Its Nasdaq Debut
markets.businessinsider.com
·
51 minutes ago
STARTRADER Spotlights ANTHUSD Pre-IPO CFD as Anthropic Files to List on Nasdaq
Bloomberg.com
·
11 hours ago
Nasdaq 100 Enters Correction as Megacap Results Amplify AI Fears
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Helus Pharma Inc.
CEO-
Employees100
Founded2019
HeadquartersToronto, Ontario, Canada
SectorPharmaceutical industry
Websitehelus.com